Literature DB >> 17339432

The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis.

Natasa Kovacić1, Ivan Kresimir Lukić, Danka Grcević, Vedran Katavić, Peter Croucher, Ana Marusić.   

Abstract

Apoptosis through Fas/Fas ligand (FasL) is an important regulator of immune system homeostasis but its role in bone homeostasis is elusive. We systematically analyzed: 1) the expression of Fas/FasL during osteoblastogenesis and osteoclastogenesis in vitro, 2) the effect of FasL on apoptosis and osteoblastic/osteoclastic differentiation, and 3) osteoblastogenesis and osteoclastogenesis in mice deficient in Fas or FasL. The expression of Fas increased with osteoblastic differentiation. Addition of FasL weakly increased the proportion of apoptotic cells in both osteoclastogenic and osteoblastogenic cultures. In a CFU assay, FasL decreased the proportion of osteoblast colonies but did not affect the total number of colonies, indicating specific inhibitory effect of Fas/FasL on osteoblastic differentiation. The effect depended on the activation of caspase 8 and was specific, as addition of FasL to osteoblastogenic cultures significantly decreased gene expression for runt-related transcription factor 2 (Runx2) required for osteoblastic differentiation. Bone marrow from mice without functional Fas or FasL had similar osteoclastogenic potential as bone marrow from wild-type mice, but generated more osteoblast colonies ex vivo. These colonies had increased expression of the osteoblast genes Runx2, osteopontin, alkaline phosphatase, bone sialoprotein, osteocalcin, and osteoprotegerin. Our results indicate that Fas/FasL system primarily controls osteoblastic differentiation by inhibiting progenitor differentiation and not by inducing apoptosis. During osteoclastogenesis, the Fas/FasL system may have a limited effect on osteoclast progenitor apoptosis. The study suggests that Fas/FasL system plays a key role in osteoblastic differentiation and provides novel insight into the interactions between the immune system and bone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339432      PMCID: PMC2774560          DOI: 10.4049/jimmunol.178.6.3379

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Runx2: a master organizer of gene transcription in developing and maturing osteoblasts.

Authors:  Tania M Schroeder; Eric D Jensen; Jennifer J Westendorf
Journal:  Birth Defects Res C Embryo Today       Date:  2005-09

Review 2.  The stem cell niches in bone.

Authors:  Tong Yin; Linheng Li
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

3.  RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.

Authors:  Sun-Kyeong Lee; Amy E Gardner; Judith F Kalinowski; Sandra L Jastrzebski; Joseph A Lorenzo
Journal:  Bone       Date:  2005-11-23       Impact factor: 4.398

4.  A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics.

Authors:  Faris Q B Alenzi; Stephen B Marley; John L Lewis; Anil Chandrashekran; Anthony N Warrens; John M Goldman; Myrtle Y Gordon
Journal:  Exp Hematol       Date:  2002-12       Impact factor: 3.084

Review 5.  Molecular mechanisms of death-receptor-mediated apoptosis.

Authors:  U Sartorius; I Schmitz; P H Krammer
Journal:  Chembiochem       Date:  2001-01-08       Impact factor: 3.164

6.  Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection.

Authors:  S Balkow; A Kersten; T T Tran; T Stehle; P Grosse; C Museteanu; O Utermöhlen; H Pircher; F von Weizsäcker; R Wallich; A Müllbacher; M M Simon
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage.

Authors:  I Kalajzic; Z Kalajzic; M Kaliterna; G Gronowicz; S H Clark; A C Lichtler; D Rowe
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

8.  Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

Authors:  C M Shipman; M J Rogers; J F Apperley; R G Russell; P I Croucher
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

9.  Differential expression of the Fas-Fas ligand system on cytokine-induced apoptotic cell death in mouse osteoblastic cells.

Authors:  Nobuaki Ozeki; Makio Mogi; Hiroshi Nakamura; Akifumi Togari
Journal:  Arch Oral Biol       Date:  2002-07       Impact factor: 2.633

10.  Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human.

Authors:  Claudia Bossen; Karine Ingold; Aubry Tardivel; Jean-Luc Bodmer; Olivier Gaide; Sylvie Hertig; Christine Ambrose; Jürg Tschopp; Pascal Schneider
Journal:  J Biol Chem       Date:  2006-03-17       Impact factor: 5.157

View more
  23 in total

1.  Chemotactic and immunoregulatory properties of bone cells are modulated by endotoxin-stimulated lymphocytes.

Authors:  Hrvoje Cvija; Natasa Kovacic; Vedran Katavic; Sanja Ivcevic; Hector Leonardo Aguila; Ana Marusic; Danka Grcevic
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

2.  Modulation of unloading-induced bone loss in mice with altered ERK signaling.

Authors:  Jeyantt S Sankaran; Bing Li; Leah Rae Donahue; Stefan Judex
Journal:  Mamm Genome       Date:  2015-11-06       Impact factor: 2.957

Review 3.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

4.  Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro.

Authors:  Shan Feng; Suzi H Madsen; Natasja N Viller; Anita V Neutzsky-Wulff; Carsten Geisler; Lars Karlsson; Kalle Söderström
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397

5.  Growth-dependent phenotype in FasL-deficient mandibular/alveolar bone.

Authors:  Eva Svandova; Jeremy Sadoine; Barbora Vesela; Amina Djoudi; Herve Lesot; Anne Poliard; Eva Matalova
Journal:  J Anat       Date:  2019-05-30       Impact factor: 2.610

Review 6.  Targeting Fas in osteoresorptive disorders.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Ana Marusic
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

Review 7.  From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.

Authors:  Stavros C Manolagas
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

8.  The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone.

Authors:  Marta Martin-Millan; Maria Almeida; Elena Ambrogini; Li Han; Haibo Zhao; Robert S Weinstein; Robert L Jilka; Charles A O'Brien; Stavros C Manolagas
Journal:  Mol Endocrinol       Date:  2010-01-06

9.  Immunology of Gut-Bone Signaling.

Authors:  Fraser L Collins; Jonathan D Schepper; Naiomy Deliz Rios-Arce; Michael D Steury; Ho Jun Kang; Heather Mallin; Daniel Schoenherr; Glen Camfield; Saima Chishti; Laura R McCabe; Narayanan Parameswaran
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

10.  Fas receptor is required for estrogen deficiency-induced bone loss in mice.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Vladimir Grubisic; Karlo Mihovilovic; Hrvoje Cvija; Peter Ian Croucher; Ana Marusic
Journal:  Lab Invest       Date:  2010-01-18       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.